Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and... The post Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update appeared first on Montreal Gazette .

Original source: Montreal Gazette